Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.35 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | ASPH | Q12797 | 2/20 | 0.34 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | HMGB1 | P09429 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL730792 | 0.83 | ALB (0.41) | ALBALDH1A1CYP1A2ALOX15KEAP1 | |
| SCHEMBL1196525 | 0.81 | DGAT1 (0.46) | ALDH1A1KDM4EHPGDCES2CES1 | |
| SCHEMBL1206852 | 0.81 | KMT2A (0.38) | ALDH1A1KDM4ECES2CES1SMN1; SMN2 | |
| SCHEMBL490677 | 0.79 | ALDH1A1 (0.48) | ALDH1A1CYP1A2ALOX15NAPRTKDM4E | |
| SCHEMBL744223 | 0.76 | GAA (0.56) | ALDH1A1KDM4EHPGDSMN1; SMN2KMT2A | |
| SCHEMBL1355068 | 0.76 | ALDH1A1 (0.41) | ALDH1A1CYP1A2KDM4ECA1CA2 | |
| SCHEMBL743830 | 0.76 | KMT2A (0.37) | ALDH1A1KEAP1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL1406514 | 0.76 | ALDH1A1 (0.48) | ALDH1A1CYP1A2ALOX15NAPRTKDM4E | |
| SCHEMBL1903574 | 0.75 | NPC1 (0.58) | ALDH1A1KDM4EHPGDSMN1; SMN2KMT2A | |
| SCHEMBL2550138 | 0.74 | ALDH1A1 (0.41) | ALDH1A1CYP1A2ALOX15NAPRTAKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113813933-B | Preparation method and adsorption application of polymer nano-sheet for precisely controlling molecular imprinting process | 深圳万知达技术转移中心有限公司 | 2024-03-19 | — | — | CN | claimed |
| US-11897891-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-02-13 | — | — | US | claimed |
| US-20230295157-A1 | 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-09-21 | — | — | US | claimed |
| EP-4185588-A1 | 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | Janssen Pharmaceutica NV (BE) | 2023-05-31 | — | — | EP | claimed |
| CN-116134035-A | 3- (1H-imidazol-2-yl) -2,3,8 a-tetrahydroindol-5 (1H) -one derivatives useful as factor XIA inhibitors | 詹森药业有限公司 | 2023-05-16 | — | — | CN | claimed |
| US-20230064443-A1 | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide Derivatives Useful As a Factor XIa Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-02 | — | — | US | claimed |
| WO-2021113479-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-06-10 | — | — | WO | claimed |
| US-20210171535-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-06-10 | — | — | US | claimed |
| US-9682940-B2 | Indazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | claimed |
| US-20170057925-A1 | INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | claimed |
| US-7696200-B2 | Bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-04-13 | — | — | US | claimed |
| EP-2131655-A2 | TRI-ARYL/HETEROAROMATIC CANNABINOIDS AND USE THEREOF | The University of Tennessee Research Foundation (US) | 2009-12-16 | — | — | EP | claimed |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-22 | — | — | US | claimed |
| CN-101379044-A | Heterobicyclic sulfonamide derivatives for the treatment of diabetes | HOFFMANN LA ROCHE (CH) | 2009-03-04 | — | — | CN | claimed |
| WO-2009012430-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-22 | — | — | WO | claimed |
| EP-1996563-A1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-03 | — | — | EP | claimed |
| US-20080234293-A1 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2008-09-25 | — | — | US | claimed |
| WO-2008109027-A2 | TRI-ARYL/HETEROAROAROMATIC CANNABINOIDS AND USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE (US) | 2008-09-12 | — | — | WO | claimed |
| WO-2007093507-A1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | claimed |
| US-20070191603-A1 | Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897891-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | ALB 4752/4885ALDH1A1 879/4885CYP1A2 931/4885 |
| US-20230295157-A1 | 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | SERPINC1, F11, TFPI2 | ALB 3599/4885ALDH1A1 2661/4885CYP1A2 714/4885 |
| US-20080234293-A1 | Tri-aryl/heteroaromatic cannabinoids and use thereof | CNR1, CNR2, OPRM1 | ALB 3706/4885ALDH1A1 1887/4885CYP1A2 176/4885 |
| US-20230064443-A1 | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide Derivatives Useful As a Factor XIa Inhibitors | F11, F12, F13A1 | ALB 3326/4885ALDH1A1 2398/4885CYP1A2 368/4885 |
| US-20210171535-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | ALB 4752/4885ALDH1A1 879/4885CYP1A2 931/4885 |
| US-20070191603-A1 | Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | ALB 4792/4885ALDH1A1 324/4885CYP1A2 357/4885 |
| US-20170057925-A1 | INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | ALB 4269/4885ALDH1A1 689/4885CYP1A2 150/4885 |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | ALB 4763/4885ALDH1A1 3091/4885CYP1A2 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.